IMV Inc.
IMV
Rank in Stocks
#35074
IMV Inc. is a clinical-stage biotechnology company dedicated to the development... IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.
Share Price
$0.82959892
Last synced: 2023-05-23
Market Cap
$4.16M
Change (1 day)
-0.04%
Change (1 year)
82,959,792.06%
Country
CA
Trade IMV Inc. (IMV)
Category
Healthcare
Stock price history for IMV Inc. (IMV)
Highest end of day price: $0.00 on 2024-04-01
Lowest end of day price: $2.79 on 2009-10-01
Lowest end of day price: $2.79 on 2009-10-01
Stock price history of IMV Inc. from 2009 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2024 | -99.62% |
| 2023 | -99.90% |
| 2022 | -80.41% |
| 2021 | -58.37% |
| 2020 | 14.77% |
| 2019 | -48.18% |
| 2018 | 1.97% |
| 2017 | 209.96% |
| 2016 | -4.32% |
| 2015 | -11.63% |
| 2014 | 46.23% |
| 2013 | 3.39% |
| 2012 | 10.27% |
| 2011 | -50.45% |
| 2010 | -42.36% |
| 2009 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
